Seconded - we need uplisting complete & positive interim data for validation. Then, I think NIAID starts saying Lenzilumab and not just "a monoclonal antibody." The NIAID is under a great deal of scrutiny right now, they have to be very calculated in everything they release to the public.
more personal speculation here: There is no way the NIAID chose to do this trial with the data from a 12 patient study alone. I believe, with their reputation on the line, the NIAID would not be moving forward with this trial unless the interim data looked promising. The NIAID trial news, while it hasn't officially been released by the institute itself, hints to me that the interim trial data is available & being prepared for public release.
News 
Market Data 
Discover 
